Bladder cancer remains one of the most common — yet often underrecognized — cancers in the United States. According to the American Cancer Society, an estimated 84,530 new bladder cancer cases and 17,870 deaths are projected nationwide in 2026. It also continues to be one of the leading causes of cancer‑related death in men.
Understanding risk factors
A family history of bladder cancer increases an individual’s risk of developing the disease.
Smoking, however, remains the most significant risk factor. Quitting smoking can sharply reduce the risk of bladder cancer and many other cancers.
Exposure to certain chemicals — including those found in tobacco smoke and environmental toxins such as arsenic — is also linked to bladder cancer because the body has difficulty breaking down these substances.
Identifying symptoms
Most patients seek medical evaluation after noticing blood in the urine, known as hematuria. This may be visible or detected only under a microscope.
If you experience blood in your urine, see a urologist promptly to rule out bladder cancer. Although many conditions can cause hematuria, bladder cancer is the most serious.
Other early symptoms can include:
- Changes in bladder habits or irritation
- Painful urination
- Increased urinary frequency or urgency
Treatment options
Bladder cancer treatment plans should be personalized to each patient’s medical needs and life circumstances.
About two‑thirds of bladder cancers are superficial, meaning they are confined to the bladder’s inner lining. These cancers are typically treated with local removal by a urologist using a scope inserted through the urethra. Some patients also receive medication placed directly into the bladder to help reduce the chance of recurrence.
The remaining one‑third of bladder cancers are invasive, penetrating the bladder wall and capable of spreading to other organs. These cases are most often treated with surgery, including cystectomy, the complete removal of the bladder.
Many patients with invasive disease may receive chemotherapy before or after surgery. Others may be treated with concurrent chemotherapy and radiation, a combination that can be effective but is generally considered slightly less curative than surgery for eligible patients.
A growing number of immunotherapy medications are available for patients whose cancer returns after surgery or spreads beyond the bladder. These treatments stimulate the body’s immune system to fight the disease.
Patients diagnosed with Stage 4 (metastatic) bladder cancer have multiple therapeutic options, including combination chemotherapy, immunotherapy and antibody‑drug conjugates.
Across all stages, the goals of bladder cancer treatment remain the same: relieve symptoms, achieve remission, control disease progression and improve survival.
LEARN MORE ABOUT BLADDER CANCER CARE AT NORTHSIDE.
References:
- American Cancer Society. “Key Statistics for Bladder Cancer.” Updated January 2026.
- Bladder Cancer Advocacy Network (BCAN). “ACS’s 2026 Bladder Cancer Projections.” January 2026.
- American Cancer Society. Cancer Facts & Figures 2026.
- Surveillance, Epidemiology, and End Results (SEER) Program. “Bladder Cancer — Cancer Stat Facts.”
- American Cancer Society Journals. “Cancer Statistics, 2026.”
